The histone methyltransferase inhibitor tazemetostat, an EZH2 inhibitor, is tested for relapsed or refractory B cell NHL with EZH2 mutations [161,162]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.